Indications and uses
To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required.
To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required.
Miochol ™ -E (acetylcholine chloride intraocular solution) is instilled into the anterior chamber before or after securing one or more sutures. Instillation should be gentle and parallel to the iris face and tangential to pupil border. If there are no mechanical hindrances, the pupil starts to constrict in seconds and the peripheral iris is drawn away from the angle of the anterior chamber. Any anatomical hindranc...
Miochol™-E (acetylcholine chloride intraocular solution) is a parasympathomimetic preparation for intraocular use. It is packaged in a blister pack containing one vial and one diluent ampule. The vial contains 20 mg acetylcholine chloride and 56 mg mannitol. The accompanying ampule contains 2 mL of a modified diluent of calcium chloride dihydrate, magnesium chloride hexahydrate, potassium chloride, sodium acetate trihydrate, and sterile water for injection.
The reconstituted liquid will be a sterile isotonic solution (275–330 milliosmoles/kg) containing 20 mg acetylcholine chloride (1:100 solution) and 2.8% mannitol. The pH range is 5.0–8.2. Mannitol is used in the process of lyophilizing acetylcholine chloride, and is not considered an active ingredient.
The chemical name for acetylcholine chloride, C7H16ClNO2, is Ethanaminium, 2-(acetyloxy)-N,N,N-trimethyl-, chloride and is represented by the following chemical structure:

Acetylcholine is a naturally occurring neurohormone which mediates nerve impulse transmission at all cholinergic sites involving somatic and autonomic nerves. After release from the nerve ending, acetylcholine is rapidly inactivated by the enzyme acetylcholinesterase by hydrolysis to acetic acid and choline.
Direct application of acetylcholine to the iris will cause rapid miosis of short duration. Topical ocular instillation of acetylcholine to the intact eye causes no discernible response as cholinesterase destroys the molecule more rapidly than it can penetrate the cornea.
To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required.
Miochol-E is contraindicated in persons with a known hypersensitivity to any component of this product.
DO NOT GAS STERILIZE. If blister or peelable backing is damaged or broken, sterility of the enclosed vial and ampule cannot be assured. Open under aseptic conditions only.
If miosis is to be obtained quickly with Miochol-E, anatomical hindrances to miosis, such as anterior or posterior synechiae, must be released, prior to administration of Miochol-E. During cataract surgery, use Miochol-E only after delivery of the lens.
Aqueous solutions of acetylcholine chloride are unstable. Prepare solution immediately before use. Do not use solution which is not clear and colorless. Discard any solution that has not been used.
Although clinical studies with acetylcholine chloride and animal studies with acetylcholine or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with topical nonsteroidal anti-inflammatory agents.
Safety and effectiveness in pediatric patients have not been established.
Infrequent cases of corneal edema, corneal clouding, and corneal decompensation have been reported with the use of intraocular acetylcholine.
Adverse reactions have been reported rarely, which are indicative of systemic absorption. These include bradycardia, hypotension, flushing, breathing difficulties, and sweating.
To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Atropine sulfate (0.5 to 1 mg) should be given intramuscularly or intravenously and should be readily available to counteract possible overdosage. Epinephrine (0.1 to 1 mg subcutaneously) is also of value in overcoming severe cardiovascular or bronchoconstrictor responses.
Miochol™-E (acetylcholine chloride intraocular solution) is instilled into the anterior chamber before or after securing one or more sutures.
Instillation should be gentle and parallel to the iris face and tangential to pupil border.
If there are no mechanical hindrances, the pupil starts to constrict in seconds and the peripheral iris is drawn away from the angle of the anterior chamber. Any anatomical hindrance to miosis must be released to permit the desired effect of the drug. In most cases, 0.5 to 2 mL produces satisfactory miosis. Note that the syringe filter supplied with Miochol-E has a priming volume of 0.6 mL (approximately).
In cataract surgery, use Miochol-E only after delivery of the lens.
Aqueous solutions of acetylcholine chloride are unstable. Prepare solution immediately before use. Do not use solution that is not clear and colorless. Discard any solution that has not been used.
STERILE UNLESS PACKAGE OPEN OR BROKEN
Discard the filter appropriately after use.
Do not reuse the syringe filter.
Do not aspirate and inject through the same filter.
Miochol™-E
(acetylcholine chloride intraocular solution)............................NDC 24208-539-20
One blister pack containing the following components:
One 0.2 micron sterile filter
Storage
Store at 4°C to 25°C (39°F to 77°F).
KEEP FROM FREEZING.
Keep out of reach of children.
Distributed by:
Bausch & Lomb Americas Inc.
Bridgewater, NJ 08807 USA
Manufactured by:
Avara Liscate Pharmaceutical Services S.p.A
20050 Liscate (Milan), Italy
Miochol is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2023 Bausch & Lomb Incorporated or its affiliates
Rev. 03/2023 | 9735301 |
NDC 24208-539-20
Miochol TM -E
(acetylcholine chloride intraocular solution)
20 mg/2 mL (10 mg/mL)
Sterile
1:100 with Electrolyte
Diluent
FOR INTRAOCULAR
USE ONLY
Rx only
Contents:
BAUSCH + LOMB
9735202
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 876551 | acetylcholine chloride 20 MG in 2 mL Ophthalmic Solution | PSN | 9 |
| 876553 | Miochol-E 20 MG in 2 mL Ophthalmic Solution | PSN | 9 |
| 876553 | acetylcholine chloride 10 MG/ML Ophthalmic Solution [Miochol] | SBD | 9 |
| 876551 | acetylcholine chloride 10 MG/ML Ophthalmic Solution | SCD | 9 |
| 876551 | acetylcholine chloride 20 MG per 2 ML (1 % ) Intraocular Solution | SY | 9 |
| 876553 | Miochol 10 MG/ML Ophthalmic Solution | SY | 9 |
| 876553 | Miochol 20 MG per 2 ML (1 % ) Intraocular Solution | SY | 9 |
| Class | Version | Type | Effective |
|---|---|---|---|
| ACETYLCHOLINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 24208-539-20 | Miochol E | 1 in 1 BLISTER PACK | KIT | 1 | 9 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 24208-539-20 | EA - Each | 24208-539 | 3608d65f-fad5-479b-a666-2c82474312ae | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACETYLCHOLINE CHLORIDE | ACTIVE INGREDIENT | AF73293C2R | 4 | |
| ACETYLCHOLINE | ACTIVE MOIETY | N9YNS0M02X | 4 | |
| CALCIUM CHLORIDE | INACTIVE INGREDIENT | M4I0D6VV5M | 4 | |
| MAGNESIUM CHLORIDE | INACTIVE INGREDIENT | 02F3473H9O | 4 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 4 | |
| POTASSIUM CHLORIDE | INACTIVE INGREDIENT | 660YQ98I10 | 4 | |
| SODIUM ACETATE | INACTIVE INGREDIENT | 4550K0SC9B | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 24208-539 | 24208-539-20 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ACETYLCHOLINE CHLORIDE | AF73293C2R | ACTIB |
| MANNITOL | 3OWL53L36A | IACT |
| CALCIUM CHLORIDE | M4I0D6VV5M | IACT |
| MAGNESIUM CHLORIDE | 02F3473H9O | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | IACT |
| SODIUM ACETATE | 4550K0SC9B | IACT |
| WATER | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | POWDER / NASAL | NA | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION / IRRIGATION | 0.04 %w/v | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | SYRUP / ORAL | 43 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAMUSCULAR | 71 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 980.4 mg | ||
| MAGNESIUM CHLORIDE | MAGNESIUM CHLORIDE | 02F3473H9O | INJECTION, SOLUTION / INTRATHECAL | 1 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION/ DROPS / OPHTHALMIC | 0.02 %w/v | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION / INTRAPERITONEAL | 0.03 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, DELAYED RELEASE / ORAL | 639 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | CREAM / TOPICAL | NA | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION / INTRALESIONAL | ADJ PH | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION / OPHTHALMIC | 9 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / INTRAVENOUS | 15400 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | INJECTION, SOLUTION / INTRATHECAL | 1 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER, FOR SUSPENSION / INTRAMUSCULAR | 6.75 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 35 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION, EXTENDED RELEASE / ORAL | 2464.6 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | 180 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION, SOLUTION / SUBCUTANEOUS | 0.16 %w/v | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION / INTRAVENOUS | 4239 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | SOLUTION / INTRAVENOUS | 20 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 141 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION / INFILTRATION | 0.3 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | INJECTION, SOLUTION / INTRA-ARTERIAL | 11 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 300 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION / INTRAOCULAR | 24 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION, SOLUTION / SUBMUCOSAL | 0.08 %w/v | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | SOLUTION / ORAL | 44 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GUM, CHEWING / BUCCAL | 891 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION / IRRIGATION | 0.04 %w/v | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION / SUBCUTANEOUS | 19 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | INJECTION, SUSPENSION / INTRAVITREAL | 0.05 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 35 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | INJECTION / INTRAMUSCULAR | 4 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBMUCOSAL | 2.94 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FOR SUSPENSION / ORAL | 7621 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / PARENTERAL | 250 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FOR SUSPENSION / ORAL | 7621 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, CONCENTRATE / INTRAVENOUS | 220 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION / OPHTHALMIC | 1 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE / ORAL | 1562 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | SOLUTION/ DROPS / OPHTHALMIC | 0.14 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING / ORAL | 4364 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | CREAM / TOPICAL | NA | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | CONCENTRATE / ORAL | 0.08 mg/1ml | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GRANULE / ORAL | 1328 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAVENOUS | 2.5 %w/v | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 0.03 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / ORAL | 869 mg | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | INJECTION, SOLUTION / INTRAVENOUS | 330 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / SUBCUTANEOUS | 4.54 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, CHEWABLE / ORAL | 3726 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAVENOUS | 2.5 %w/v | ||
| POTASSIUM CHLORIDE | POTASSIUM CHLORIDE | 660YQ98I10 | POWDER / RESPIRATORY (INHALATION) | 0.18 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION, SOLUTION / SUBCUTANEOUS | 0.16 %w/v | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | SOLUTION / INTRAOCULAR | 24 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | SOLUTION / INTRAOCULAR | 195 mg | ||
| CALCIUM CHLORIDE | CALCIUM CHLORIDE | M4I0D6VV5M | INJECTION, SOLUTION / INTRAVENOUS | 11 mg | ||
| SODIUM ACETATE | SODIUM ACETATE | 4550K0SC9B | INJECTION, SUSPENSION / INTRAVITREAL | 0.39 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020213-001 | MIOCHOL-E | ACETYLCHOLINE CHLORIDE | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N020213-001 | MIOCHOL-E | 20MG/VIAL | FOR SOLUTION / OPHTHALMIC | RLD, RS | 1993-09-22 | 3bdfa0b2c4d7… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Miochol E | ACETYLCHOLINE CHLORIDE | Bausch & Lomb Incorporated | e701ef07-9499-4b56-931f-f4eb3eedbe24 | 2023-03-17 | Warnings, Adverse reactions | 24208-539-20 24208-539 24208053920 19c42ee4-9f98-48da-85ea-52090070c2e2 e701ef07-9499-4b56-931f-f4eb3eedbe24 |
Adverse event summaries are temporarily unavailable. Other product information remains available.